---
title: "Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data"
date: "2025-02-07 20:50:07"
summary: "Novo Nordisk&#39;s phase 3 trial of Mim8 in children with hemophilia A showed a 0.53 mean annualized bleeding rate, with 74.3% reporting zero treated bleeds."
categories:
  - "benzinga"
lang:
  - "en"
translations:
  - "en"
tags:
  - "benzinga"
menu: ""
thumbnail: "https://www.benzinga.com/files/images/story/2025/02/07/Ozempic-maker-Novo-Nordisk.jpeg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Novo Nordisk's phase 3 trial of Mim8 in children with hemophilia A showed a 0.53 mean annualized bleeding rate, with 74.3% reporting zero treated bleeds.

[benzinga](https://www.benzinga.com/general/biotech/25/02/43557877/novo-nordisk-eyes-2025-regulatory-filing-for-hemophilia-candidate-after-encouraging-pediatric-study-data)
